Elevated levels of serum sialic acid and high-sensitivity inflammation in patients with chronic heart failure C-reactive protein: Markers of systemic

British Journal of Biomedical Science

Volumn 71, Issue 1, 2014, Pages 29-32

  Rajendiran, K S ^a   Ananthanarayanan, P H ^a   Satheesh, S ^a   Rajappa, M ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

C reactive protein; Heart failure; Inflammation; Sialic acid

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; LIPID ASSOCIATED SIALIC ACID; SIALIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART FAILURE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 84898000893     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2014.11669959     Document Type: Article

References (30)

1. Dickstein K, Cohen-Solal A, Filippatos G et al.; ESC Committee for Practice Guideleines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29 (19): 2388-442.
2. Fox KF, Cowie MR, Wood DA et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 2001; 22 (3): 228-36. (Pubitemid 32622473)
3. McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005; 365 (9474): 1877-89. (Pubitemid 40744967)
4. Oikonomou E, Tousoulis D, Siasos G, Zaromitidou M, Papavassiliou AG, Stefanadis C. The role of inflammation in heart failure: new therapeutic approaches. Hellenic J Cardiol 2011; 52 (1): 30-40.
5. Silllanaukee P, Ponnio M, Jaaskelainen IP. Occurrence of sialic acids in healthy humans and different disorders. Eur J Clin Invest 1999; 29 (5): 413-25. (Pubitemid 29209762)
6. Schauer R. Sialic acids and their role as biological masks. Trends in Biochemical Sciences 1985; 10 (9): 357-60. (Pubitemid 16220327)
7. Nigam PK, Narain VS, Ajay Kumar. Sialic acid in cardiovascular diseases. Indian J Clin Biochem 2006; 21 (1): 54-61.
8. Gopaul KP, Crook MA. Sialic acid: a novel marker of cardiovascular disease? Clin Biochem 2006; 39 (7): 667-81. (Pubitemid 44055927)
9. Nanettib L, Vignini A, Raffaelli F et al. Sialic acid and sialidase activity in acute stroke. Dis Markers 2008; 25 (3): 167-73.
10. Gokmen SS, Kilicli G, Ozcelik F, Ture M, Gulen S. Association between serum total and lipid-bound sialic acid concentration and the severity of coronary atherosclerosis. J Lab Clin Med 2002; 140 (2): 110-8. (Pubitemid 35028785)
11. Browning LM, Krebs JD, Jebb SA. Discrimination ratio analysis of inflammatory markers: implications for the study of inflammation in chronic disease. Metabolism 2004; 53 (7): 899-903. (Pubitemid 38829465)
12. Melaji N, Cylliing H, Miettinen TA. Sialic acids and the metabolism of low density 1ipoprotein. J Lipid Res 1996; 37 (8): 1625-31. (Pubitemid 26275373)
13. Moraes JC, Ribeiro AC, Saad CG, Lianza AC, Silva CA, Bonfa E. NT-proBNP levels may be influenced by inflammation in active ankylosing spondylitis receiving TNF blockers: a pilot study. Clin Rheumatol 2013; 32 (6): 879-83.
14. National Cholesterol Education Program. Second report of the expert panel on detection evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 89 (3): 1333-445.
15. Friedwald WT, Laby RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18 (6): 499-502.
16. Blick KE. Economics of point-of-care (POC) testing for cardiac markers and B-natriuretic peptide (BNP). Point of Care 2005; 4: 11-4.
17. Aminoff D. Methods for the quantitative estimation of N-acetyl neuraminic acid and their application to hydrolysates of sialomucoids. Biochem J 1961; 81: 384-92.
18. Katopodis N, Hirshaut Y, Geller NL, Stock CC. Lipid-associated sialic acid test for the detection of human cancer. Cancer Res 1982; 42 (12): 5270-5. (Pubitemid 13223181)
19. Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure - the whys and wherefores. Heart Fail Rev 2006; 11 (1): 83-92. (Pubitemid 43986210)
20. Topcuoglu C, Yilmaz FM, Sahin D et al. Total and lipid associated sialic acid in serum and thrombocytes in patients with chronic heart failure. Clin Biochem 2010; 43 (4-5): 447-9.
21. Crook M, Haq M, Haq S, Tutt P. Plasma sialic acid and acute phase proteins in patients with myocardial infarction. Angiology 1994; 45 (8): 709-15. (Pubitemid 24250748)
22. Gracheva EV, Samovilova NN, Golovanova NK et al. Sialyltransferase activity of human plasma and aortic intima is enhanced in atherosclerosis. Biochim Biophys Acta 2002; 1586 (1): 123-8. (Pubitemid 34066623)
23. Lindberg G, Eklund GA, Gullberg B, Rastam L. Serum sialic acid concentration predicts both coronary heart disease and stroke mortality: multivariate analysis including 54385 men and women during 20.5 years follow up. Int J Epidemiol 1992; 21 (2): 253-7.
24. Tertov VV, Sobenin IA, Gabbasov ZA, Popov EG, Orekhov AN. Lipoprotein aggregation as an essential condition of intracellular lipid accumulation caused by modified low density lipoproteins. Biochem Biophys Res Commun 1989; 163 (1): 489-94. (Pubitemid 19227332)
25. Orekhov AN, Tertov VV, Pokrovsky SN et al. Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low density lipoproteins and an approach to its elimination. Circ Res 1988; 62 (3): 421-9. (Pubitemid 18078680)
26. Taniuchi K, Chifu K, Hayashi N et al. A new enzymatic method for the determination of sialic acid in serum and its application for a marker of acute phase reactants. Kobe J Med Sci 1981; 27 (3): 91-102. (Pubitemid 11029070)
27. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 2004; 90 (3): 297-303. (Pubitemid 38250725)
28. Crowson CS, Myasoedova E, Davis JM et al. Use of B-type natriuretic peptide as a screening tool for left ventricular diastolic dysfunction in rheumatoid arthritis patients without clinical cardiovascular disease. Arthritis Care Res (Hoboken) 2011; 63 (5): 729-34.
29. Sanchez-Lazaro IJ, Almenar L, Reganon E et al. Inflammatory markers in stable heart failure and their relationship with functional class. Int J Cardiol 2008; 129 (3): 388-93.
30. Sathiyapriya V, Nandeesha H, Selvaraj N, Bobby Z, Agrawal A, Pavithran P. Association between protein-bound sialic acid and high-sensitivity C-reactive protein in essential hypertension: a possible indication of underlying cardiovascular risk. Angiology 2009; 59 (6): 721-6.